Stockreport
PDE4 Inhibitor Market to Exhibit Substantial Growth Rate During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
With an increasing understanding of their therapeutic potential and advancements in drug delivery technologies, PDE4 inhibitors are anticipated to witness heightened demand. Moreover, their potential applications in treating psychiatric disorders further contribute to the optimistic growth projections for the PDE4 inhibitor market. New York, USA, June 25, 2024 (GLOBE NEWSWIRE) -- PDE4 Inhibitor Market to Exhibit Substantial Growth Rate During the Study Period (2020–2034) | DelveInsight The PDE4 inhibitor market is poised for substantial growth in the coming years, driven by expanding research in inflammatory and autoimmune diseases. With an increasing understanding of their therapeutic potential and advancements in drug delivery technologies, PDE4 inhibitors are anticipated to witness heightened demand. Moreover, their potential applications in treating psychiatric disorders further contribute to the optimistic growth projections for the PDE4 inhibitor market. DelveInsight's PDE
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Coherus offloads Humira biosimilar Yusimry for $40m [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Argus from $300.00 to $340.00. They now have a "buy" rating on the stock.[MarketBeat]
- Comprehensive Diabetic Neuropathy Pipeline Insight Report for 2024 Reveals Progress in Treatment Landscape [Yahoo! Finance][Yahoo! Finance]
- Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications [Yahoo! Finance][Yahoo! Finance]
- Global Pharmaceutical Marketing Industry Research Report 2024-2030: Market Size Projections for Conference Marketing, PPC Advertising, Print Advertising, Social Media Campaigns, TV Commercials, and More [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 6/21/24 - Form 11-K
- 6/21/24 - Form 11-K
- 6/12/24 - Form S-8
- AMGN's page on the SEC website
- More